How each drug works: one receptor versus two
Semaglutide is a GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1, a hormone the gut naturally releases after eating. When the GLP-1 receptor is activated, gastric emptying slows so food stays in the stomach longer, the pancreas releases insulin in response to rising blood sugar, and satiety signals reach the brain to reduce hunger. The overall effect is a reduction in appetite and calorie intake over time.
Tirzepatide activates two receptors instead of one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is a second incretin hormone released by the small intestine after eating. Research published in 2022 established that tirzepatide functions as an imbalanced dual agonist, a single molecule designed to engage both pathways in a coordinated way rather than acting as a simple combination of two separate drugs (Chavda et al., Frontiers in Pharmacology, 2022). The GIP component appears to enhance the appetite-suppressing effect of GLP-1 stimulation and may also partially counteract some of the nausea that GLP-1 activation can produce.
In practical terms: both drugs slow gastric emptying, reduce food intake, and act on brain areas that regulate hunger. Tirzepatide does this through an additional pathway, which helps explain why clinical trial results differ between the two drugs. Both require a once-weekly subcutaneous injection and both work best alongside a healthy diet and regular physical activity.
Dosing: how each drug is titrated over time
Both medications start at a low dose and increase gradually over several months. This escalation is designed to reduce gastrointestinal side effects during the adjustment period, not because the starting dose has a meaningful effect on weight.
Semaglutide (Wegovy, for weight management): Begins at 0.25 mg once weekly for four weeks, then increases every four weeks through 0.5 mg, 1.0 mg, and 1.7 mg, reaching the target maintenance dose of 2.4 mg at approximately week 17. Patients who cannot tolerate 2.4 mg may remain at 1.7 mg.
Tirzepatide (Zepbound, for weight management): Begins at 2.5 mg once weekly for four weeks, then increases in 2.5 mg steps every four weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg. Approved maintenance doses are 5 mg, 10 mg, or 15 mg depending on response and tolerability.
Both schedules take four to five months to reach full maintenance dosing. Rushing through titration is a common source of severe nausea and is not recommended. A licensed provider manages the titration plan and may slow the pace based on how a patient tolerates each step. Injection sites for both drugs include the abdomen, outer thigh, and upper arm, rotated each week.
STEP 1: semaglutide's pivotal weight-loss trial
The STEP 1 trial was the landmark study supporting FDA approval of Wegovy for chronic weight management. Published in the New England Journal of Medicine in 2021, it enrolled 1,961 adults with a body mass index (BMI) of 30 or higher, or BMI of 27 or higher with at least one weight-related condition, who did not have type 2 diabetes. All participants received behavioral counseling alongside weekly injections of Wegovy or placebo (Wilding et al., NEJM, 2021).
At 68 weeks, participants using Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of their body weight, compared with 2.4% in the placebo group. A total of 86.4% of participants on Wegovy achieved at least 5% weight reduction, versus 31.5% on placebo.
Important note: These results are for FDA-approved Wegovy (semaglutide 2.4 mg) tested in a specific trial population under defined conditions. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials. Individual outcomes with any treatment vary based on starting weight, dose, adherence, and personal health factors.
SURMOUNT-1: tirzepatide's pivotal weight-loss trial
The SURMOUNT-1 trial supported FDA approval of Zepbound for chronic weight management. Published in the New England Journal of Medicine in 2022, it enrolled 2,539 adults with obesity or overweight and at least one weight-related comorbidity who did not have type 2 diabetes. Participants were randomly assigned to one of three tirzepatide doses or placebo for 72 weeks (Jastreboff et al., NEJM, 2022).
Mean body weight change from baseline at 72 weeks by dose:
- Tirzepatide 5 mg: -15.0%
- Tirzepatide 10 mg: -19.5%
- Tirzepatide 15 mg: -20.9%
- Placebo: -3.1%
Because SURMOUNT-1 and STEP 1 enrolled different trial populations, used slightly different follow-up periods (72 vs. 68 weeks), and had separate placebo arms, the numbers above cannot be used as a direct drug-to-drug comparison. They are each trial-specific results reflecting conditions unique to that study. A true head-to-head comparison requires the same population tested at the same time, which brings us to SURMOUNT-5.
Important note: These results are for FDA-approved Zepbound (tirzepatide) in a defined trial population. Compounded tirzepatide is not FDA-approved and has not been evaluated in equivalent clinical trials.
SURMOUNT-5: the first direct head-to-head trial
SURMOUNT-5 is the first randomized controlled trial to compare semaglutide and tirzepatide directly in the same population at the same time. Results were published in the New England Journal of Medicine in 2025. The trial enrolled 751 adults with obesity (without type 2 diabetes) and randomly assigned them to tirzepatide (maximum tolerated dose up to 15 mg) or semaglutide (maximum tolerated dose up to 2.4 mg) for 72 weeks, alongside a structured behavior support program (SURMOUNT-5, NEJM, 2025).
Results at 72 weeks:
- Tirzepatide: mean weight change -20.2% (averaging 22.8 kg lost)
- Semaglutide: mean weight change -13.7% (averaging 15.0 kg lost)
- Participants losing 30% or more of body weight: 19.7% on tirzepatide vs. 6.9% on semaglutide
- Mean waist circumference reduction: 18.4 cm (tirzepatide) vs. 13.0 cm (semaglutide)
The difference favoring tirzepatide was statistically significant (p less than 0.001). Because this is a true head-to-head randomized trial with a single shared population and the same 72-week follow-up, SURMOUNT-5 is the most direct published evidence comparing average weight loss between the two approved drugs in adults without diabetes.
Important note: These results are for FDA-approved Wegovy and Zepbound only. Compounded semaglutide and compounded tirzepatide are not FDA-approved and have not been evaluated in equivalent clinical trials.
Side effect profiles: where they differ
The most common side effects for both drugs are gastrointestinal: nausea, diarrhea, vomiting, constipation, and stomach discomfort. These are most frequent during dose escalation and tend to improve once a maintenance dose is reached. Both drugs share a boxed warning about a potential risk of thyroid C-cell tumors observed in rodent studies; a causal relationship in humans has not been established, but neither drug should be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. A licensed provider screens for these contraindications before writing a prescription.
The two drugs differ in their GI profile in a few specific ways:
- Nausea and vomiting: More common with semaglutide. A 2025 preclinical study found that GIP receptor activation, one of tirzepatide's two mechanisms, may partially block the nausea response triggered by GLP-1 stimulation (Borner et al., PMC, 2025). This biological difference may explain why nausea rates are lower with tirzepatide in clinical settings.
- Diarrhea: Somewhat more commonly reported with tirzepatide across clinical trial data.
- Constipation: More frequently associated with semaglutide, which produces a stronger delay in gastric emptying than tirzepatide.
In the SURMOUNT-5 head-to-head trial, gastrointestinal side effects led to treatment discontinuation in 5.6% of the semaglutide group versus 2.7% of the tirzepatide group (SURMOUNT-5, NEJM, 2025). Slower dose titration reduces the severity of GI side effects with both drugs.
Important note: These tolerability figures are for FDA-approved Wegovy and Zepbound tested in SURMOUNT-5. Compounded semaglutide and compounded tirzepatide are not FDA-approved and have not been evaluated in equivalent clinical trials.
Semaglutide vs tirzepatide: key differences at a glance
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single target) | GLP-1 + GIP receptor agonist (dual target) |
| FDA approval for weight management | June 2021 | November 2023 |
| Injection frequency | Once weekly | Once weekly |
| Dose range | 0.25 mg to 2.4 mg | 2.5 mg to 15 mg |
| Mean weight loss, pivotal trial | -14.9% at 68 weeks (STEP 1) | -20.9% at 15 mg, 72 weeks (SURMOUNT-1) |
| Mean weight loss, head-to-head (SURMOUNT-5) | -13.7% at 72 weeks | -20.2% at 72 weeks |
| Most common GI side effects | Nausea, constipation | Diarrhea, nausea |
| GI-related discontinuation (SURMOUNT-5) | 5.6% | 2.7% |
| Approved for adolescents (weight management) | Yes, ages 12 and older | No (adults only for weight management) |
| Oral formulation available | Yes | Not available |
| Cardiovascular outcome data | SELECT trial: 20% MACE reduction | SURPASS-CVOT cardiovascular outcome trial (consult current sources for status) |
| Approximate cash-pay price (manufacturer savings) | ~$349/mo (NovoCare, 2026) | ~$299-$449/mo (LillyDirect, 2026) |
Note: All trial data in this table refers to FDA-approved brand medications only. Compounded semaglutide and compounded tirzepatide are not FDA-approved and have not been evaluated in equivalent trials. Cross-trial comparisons (STEP 1 vs. SURMOUNT-1) involve different populations and timepoints; SURMOUNT-5 is the only direct head-to-head comparison.
Cost at list price and manufacturer savings programs
Without insurance, both Wegovy and Zepbound carry retail list prices above $1,000 per month. Both manufacturers offer cash-pay savings programs that reduce costs substantially for patients who qualify.
Novo Nordisk's NovoCare pharmacy program prices Wegovy at approximately $349 per month for doses up to 2.4 mg and $399 per month for the higher-dose formulation, as of 2026 (Wegovy.com, 2026). Eli Lilly's LillyDirect self-pay program prices Zepbound at approximately $299 to $449 per month depending on dose, following a pricing update in late 2025 (GoodRx, 2026).
Insurance coverage for weight management GLP-1 medications remains inconsistent. Most commercial plans do not cover these drugs for obesity alone unless the patient has a separate qualifying condition such as type 2 diabetes or established cardiovascular disease. Medicare coverage for weight management medications continues to evolve. Prices and plan policies change frequently, and a pharmacist or care team can confirm current costs before treatment begins.
How providers choose between the two drugs
The American College of Physicians recommended both semaglutide and tirzepatide as first-line pharmaceutical options for adults with a BMI of 30 or higher, or BMI of 27 or higher with a weight-related comorbidity, in updated guidance published in 2026 (Medscape, 2026). Neither drug is automatically the right answer for every person. Providers evaluate several clinical factors alongside patient preference.
Factors that may favor semaglutide:
- History of cardiovascular disease: The SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, over an average 33-month follow-up (Lincoff et al., NEJM, 2023).
- Age 12 to 17: Wegovy is FDA-approved for weight management in adolescents; Zepbound is not approved for adolescent weight management.
- Preference for a non-injectable option: An oral formulation of semaglutide for weight management is taken once daily on an empty stomach.
- More years of post-market real-world data due to earlier approval date.
Factors that may favor tirzepatide:
- Greater average weight loss in head-to-head data: SURMOUNT-5 showed tirzepatide produced 6.5 percentage points more weight loss on average than semaglutide in the same population.
- Obstructive sleep apnea: Tirzepatide received FDA approval for reducing the severity of moderate-to-severe obstructive sleep apnea in adults with obesity, backed by dedicated clinical trial evidence.
- Lower nausea-driven discontinuation rate based on SURMOUNT-5 tolerability data (2.7% vs. 5.6%).
Access, insurance coverage, personal tolerability, and prior medication history all shape the final decision. The provider evaluates all of these factors alongside the patient's goals and medical history. No universal ranking makes one drug correct for everyone.
Important note: All clinical trial data cited in this section refers to FDA-approved Wegovy and Zepbound. Compounded semaglutide and compounded tirzepatide are not FDA-approved and have not been evaluated in equivalent clinical trials. Individual results with any treatment vary.
A note on compounded semaglutide and tirzepatide
Every clinical result discussed in this article, including STEP 1, SURMOUNT-1, and SURMOUNT-5, was produced using FDA-approved branded formulations: Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide). Compounded versions of these drugs are a separate category that requires a clear explanation.
Compounded semaglutide and compounded tirzepatide are prepared by licensed compounding pharmacies for individual patients under a valid prescription. These products are not FDA-approved. The FDA does not review compounded drugs for safety, efficacy, or quality before they are dispensed. No published clinical trial has tested compounded semaglutide or compounded tirzepatide under the same conditions as the brand trials described above, and no equivalence to the brand drugs has been established by clinical evidence.
Licensed outsourcing facilities with FDA 503B registration are subject to current good manufacturing practice standards. State-licensed 503A pharmacies operate under state pharmacy board oversight. The accurate way to describe such a facility is "FDA-registered 503B outsourcing facility," not "FDA-approved facility," a distinction the FDA has enforced through waves of warning letters to telehealth companies issued between 2025 and 2026. Any telehealth program offering compounded GLP-1 medications should clearly explain that the trial data in articles like this one does not apply to the compounded product, and that results may differ. A licensed provider can help weigh the available options based on an individual's health profile and goals.